Abstract:Abstract Introduction The prognosis for patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) is very poor under current therapeutic modalities. Recently chimeric antigen receptor modified T cells against CD19 (CART19) have shown promise as a novel therapy for R/R ALL patients in clinical trials. In our clinical trial, we found that CART19 had potent anti-leukemia activities in Chinese patients with R/R ALL (Yongxian Hu, He Huang et al; No.O168, oral presentation, EBMT 2016). In the current study we sought to determine whether CART19, results in better clinical outcomes in patients with R/R ALL than does chemotherapy (ChiCTR- ORN-16008948). Methods We compared the effectiveness and toxicities of CART19 therapy in 17 R/R ALL patients (CART19 group) against a historical control group of 42 patients who received standard or salvage chemotherapy (Chemotherapy group). For some patients who relapsed after allogeneic hematopoietic stem cell transplantation (HSCT), donor lymphocyte infusion and chemotherapy were combined. Results 7 (41.2%) and 15 (35.7%) patients were relapsed after allogeneic HSCT in the CART19 group and the chemotherapy group respectively. The rate of complete remission was significantly higher in the CART19 group than in the chemotherapy group (93.3% [95% confidence interval (CI), 68.1 to 99.8] vs. 40.5% [95% CI, 25.6 to 56.7], P<0.001). Among the patients who had complete remission, a higher percentage in the CART19 group had results below the threshold for minimal residual disease (0.01% marrow blasts) (100% vs 23.7%, P<0.001). 5 (29.4%) and 2 (4.8%) of patients who achieved complete remission in the 2 groups underwent subsequent haploidentical HSCT (2 for the second transplantation). In the survival analysis, the overall survival rate at 12 months was significantly higher in the CART19 group than in the chemotherapy group (65.4% vs 14.6% hazard ratio, 0.36 [95 % CI, 0.20 to 0.81]; P=0.0175) (Figure 1A). In the chemotherapy group, the causes of death included primary disease progression (24 patients), infection (10 patients) and intracranial hemorrhage (1 patient) while in the CART19 group the causes of death included primary disease progression (3 patients) and infection (3 patients). Cytokine release syndrome (CRS) was the most side effect in CART19 therapy. 12 (70.6%) of 17 patients suffered from CRS. The Grade 3 CRS developed in 6 (35.3%) of patients. The CRS syndrome was fully reversible after treatment with supportive care alone (n=6), supportive care plus the anti-interleukin-6 receptor monoclonal antibody, tocilizumab (n=3), supportive care plus tocilizumab and corticosteroids (n=2), as well as supportive care plus corticosteroids (n=1). CART19-related other adverse events were reversible neurotoxicity and pancytopenia consistent with previous reports. In the chemotherapy group, pancytopenia was the major toxicity. For patients who achieved complete remission, the median duration of absolute neutrophil count less than 500/¦ÌL was longer in the CART19 group than in the chemotherapy group [22.07±7.66 days (95% CI , 17.65 to 26.49) vs 16.06±3.66 days (95% CI , 14.17 to 17.94) , p=0.0076] (Figure 1B). Conclusions For the first time our study found thatCART19 therapy could greatly improved rates of complete remission and overall survival compared to conventional chemotherapy in R/R ALL patients. Our data suggest that CART19 turns to provide a new therapeutic approach for patients with R/R ALL. This novel targeted immune therapy provides more patients with R/R ALL opportunities for further interventional therapeutic strategies such as the secondary CART19 therapy, targeted drug therapy and haploidentical HSCT, even the second allo-HSCT, to improve the long-term overall clinical outcomes in patients with high-risk of relapse after CART19 therapy. Disclosures No relevant conflicts of interest to declare.

Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

Superior Therapeutic Efficacy of Chimeric Antigen Receptor Modified T Cells Against CD19 over Chemotherapy in Relapsed/Refractory Acute Lymphocytic Leukemia

Potent Anti-Leukemia Activities of Humanized CD19-targeted Chimeric Antigen Receptor T (CAR-T) Cells in Patients with Relapsed/refractory Acute Lymphoblastic Leukemia.

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy

Cd19 Targeted Chimeric Antigen Receptor T (Car-T) Cell Immunotherapy Has Demonstrated Significant Anti-Leukemia Activity In Pediatric Patients With Relapsed/Refractory Acute Lymphocytic Leukemia: A Multicentre Study In China.

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia

Advances of CD19-directed Chimeric Antigen Receptor-Modified T Cells in Refractory/relapsed Acute Lymphoblastic Leukemia

Progress in clinical application of chimeric antigen receptor-T cells for the refractory and relapsed B-cell leukemia

Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Potent Anti-Leukemia Activities of Chimeric Antigen Receptor-Modified T Cells Against Cd19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

New development in CAR-T cell therapy

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL

Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy

Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy